Latest Oncology News

Niraparib Plus Dostarlimab Misses the Mark in Platinum-Resistant Ovarian Cancer

Niraparib Plus Dostarlimab Misses the Mark in Platinum-Resistant Ovarian Cancer

June 25th 2022

Kristi Rosa

The combination of niraparib and dostarlimab produced a low overall response rate in patients with platinum-resistant ovarian cancer without a known BRCA mutation who had progressed and received prior bevacizumab, one that did not reach the threshold for second-stage accrual to the phase 2 MOONSTONE/GOG-3032 trial.

FDA Approves Liso-cel for Second-Line Relapsed/Refractory LBCL

FDA Approves Liso-cel for Second-Line Relapsed/Refractory LBCL

June 24th 2022

Caroline Seymour

The FDA has approved lisocabtagene maraleucel as second-line therapy for adult patients with large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

Amivantamab/Lazertinib Combo Demonstrates Durable Activity in EGFR-Mutated NSCLC

Amivantamab/Lazertinib Combo Demonstrates Durable Activity in EGFR-Mutated NSCLC

June 24th 2022

Kristi Rosa

The combination of amivantamab-vmjw and lazertinib produced encouraging responses with acceptable safety in patients with EGFR-mutated non–small cell lung cancer who expressed on osimertinib and platinum-based chemotherapy.

Wenham Discusses the Growing Treatment Landscape Across Gynecologic Cancers

Wenham Discusses the Growing Treatment Landscape Across Gynecologic Cancers

June 24th 2022

Ryan Scott

Robert Wenham, MD, MS, FACOG, FACS, discusses the current treatment landscape for patients with cervical and endometrial cancers, ADCs and PARP inhibitors in ovarian cancer, advancements in HER2-positive breast cancer, and surgical options for patients with ovarian cancer.

Tamibarotene Highlights Novel Treatment Strategy in RARA+ AML

Tamibarotene Highlights Novel Treatment Strategy in RARA+ AML

June 24th 2022

Kyle Doherty

Retinoic acid receptor α, a gene overexpressed in approximately 30% of unfit patients with newly diagnosed acute myeloid leukemia, has emerged as a potential therapeutic target.

Latest Oncology Videos

All Oncology News

Orca-T Continues to Break New Ground in Hematologic Cancers

June 9th 2022

Gina Mauro

Samer Srour, MD, discusses his experiences with the Orca-T and Orca-Q programs, and highlights how this type of treatment is shifting the field of hematologic malignancies.

Multiple Myeloma: Sequencing Novel Bispecific and CAR T-Cell Therapies

June 9th 2022

Luciano J. Costa, MD, PhD

In light of emerging bispecific and CAR T-cell therapies in multiple myeloma, experts consider how they might optimally sequence treatment.

Myelofibrosis: Patient Monitoring and Triggers to Change Therapy

June 9th 2022

Stephen Oh, MD, PhD

Expert perspectives on monitoring patients receiving therapy for myelofibrosis, with additional considerations for when it is appropriate to switch therapy.

Role of MRD in Treatment Decision Making in AML

June 9th 2022

Richard M. Stone, MD

Two experts discuss the clinical implications of minimal residual disease (MRD) and how it has affected treatment for patients with acute myeloid leukemia (AML).

MonumenTAL-1: Talquetamab in Relapsed or Refractory Multiple Myeloma

June 9th 2022

Luciano J. Costa, MD, PhD

Comprehensive discussion on the MonumenTAL-1 trial of talquetamab, a GPRC5D- and CD3-targeted agent, in the setting of relapsed/refractory multiple myeloma.

Considerations for Venetoclax + Azacitidine Administration and AE Management

June 9th 2022

Richard M. Stone, MD

Richard Stone, MD, and Eunice Wang, MD, discuss considerations and challenges related to the administration of venetoclax and azacitidine in the community setting, and share strategies for managing adverse events associated with this combination.

Selection and Management of JAK Inhibitor Therapy in MF

June 9th 2022

Pankit Vachhani, MD, University of Alabama at Birmingham Hospital

Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.

Mosunetuzumab Approved in Europe for Relapsed/Refractory Follicular Lymphoma

June 8th 2022

Kristi Rosa

The European Commission has granted a conditional marketing authorization for mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 systemic therapies.

Trends and Disparities in Treatment Approaches for Patients With Locoregional ESCC

June 8th 2022

John Marshall, MD

Shared insights on contemporary approaches to treating localized ESCC and existing racial disparities in treatment.

Bristol Myers Squibb Withdraws sBLA for Luspatercept-aamt in Non–Transfusion Dependent Beta Thalassemia

June 8th 2022

Kristi Rosa

The global biopharmaceutical company Bristol Myers Squibb has announced the withdrawal of a supplemental biologics license application that was seeking the approval of luspatercept-aamt for the treatment of anemia in adults with non–transfusion dependent beta-thalassemia.

A Survey of Patient Presentation, Testing, and Diagnosis in ESCC

June 8th 2022

John Marshall, MD

Broad discussion from expert John Marshall, MD, on the current standards of diagnosis care in esophageal squamous cell carcinoma (ESCC).

PSA Response Following Darolutamide Triplet Linked to OS Benefit in mHSPC

June 8th 2022

Jason M. Broderick

Treatment with darolutamide, androgen deprivation therapy, and docetaxel that elicited a PSA response was linked to improved overall survival in patients with metastatic hormone-sensitive prostate cancer.

New Chief of Bone Marrow Transplant and Cellular Therapies Named to New Jersey’s Only NCI-Designated Comprehensive Cancer Center

June 8th 2022

Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Ira Braunschweig, MD, as chief, Section of Transplant and Cell Therapy at Rutgers Cancer Institute, chief of the Transplant and Cell Therapy Service of the RWJBarnabas Health Oncology Service Line, and director for Cell Therapy and Bone Marrow Transplantation at Robert Wood Johnson University Hospital.

BRUIN CLL-321 Aims to Expand BTK Inhibitor Options in CLL/SLL

June 8th 2022

Kyle Doherty

The BRUIN CLL-321 trial is evaluating pirtobrutinib monotherapy compared with investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received covalent BTK inhibitor treatment.

Optimizing Treatment Strategies in Breast Cancer: Q&A

June 8th 2022

Joyce A. O'Shaughnessy, MD

Fielding questions from their live audience, Joyce O'Shaughnessy, MD, and Sara Hurvitz, MD, discuss optimal selection of therapy for patients with breast cancer.

See All News